479TiP - Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Anticancer Agents
Translational Research
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter Daniel Tan
Citation Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532
Authors D. Tan1, C. Lin2, D. Chin-Lun Huang3, H. Jung4, T. Bogenrieder5, K. Park6
  • 1Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 2Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei/TW
  • 3Oncology Department, Boehringer Ingelheim Taiwan Limited, Taipei/TW
  • 4Oncology Department, Boehringer Ingelheim Korea, Seoul/KR
  • 5Oncology Department, Boehringer Ingelheim RCV, Vienna/AT
  • 6Division Of Hematology-oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR



In preclinical studies, insulin-like growth factor (IGF) signaling has been implicated in acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This trial evaluates BI 836845, an IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 and neutralizes growth-promoting signaling, combined with afatinib in patients (pts) with EGFR-mutated NSCLC.

Trial design

This open-label, dose-escalation trial in Korea, Taiwan and Singapore (NCT02191891; 1280.16) consists of a dose confirmation part (Part A) followed by an expansion part (Part B). Eligible pts are aged ≥18 years with advanced and/or metastatic NSCLC progressing during prior treatment with EGFR TKI or platinum-based chemotherapy (Part A) or prior EGFR TKIs (Part B), with a documented activating EGFR mutation and no EGFR T790M mutation (Part B only). Pts with prior afatinib therapy below assigned dose level (Part A only) or <30 mg/day (Parts A and B), or progressive disease (PD) on an insufficient dose of EGFR TKI prior to study in investigator's opinion, or >2 (Part B only) prior EGFR TKI regimens for relapsed/metastatic NSCLC are excluded. Part A uses a 3 + 3 design to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836845 plus afatinib (starting dose: BI 836845 1000 mg/week 1-hour intravenous infusion plus oral afatinib 30 mg/day in 4-week courses). Pts receive treatment until PD, intolerability or study discontinuation. In Part A, pts are entered sequentially into escalating/de-escalating dose tiers (3–6 pts/cohort) to determine the MTD based on dose-limiting toxicities (DLTs) during Course 1; 6 additional pts will be enrolled in an extension cohort at the RP2D. In Part B, two expansion cohorts of 18 pts previously treated with irreversible EGFR TKIs (e.g. afatinib, dacomitinib; Cohort 1) or reversible EGFR TKIs (gefitinib or erlotinib; Cohort 2) will receive the RP2D determined in Part A. Primary endpoints are MTD and DLTs during Course 1 (Part A) and objective response (OR; Part B). Secondary endpoints include disease control, time to OR, duration of OR, and pharmacokinetics. All analyses will be descriptive and exploratory.

Clinical trial identification

NCT02191891; Study 1280.16


D. Chin-Lun Huang, H. Jung, T. Bogenrieder: employment: Boehringer Ingelheim. HK. Park: Advisory board: Astellas, AZ, BI, Clovis, Eli Lilly, Hanmi, KHK, Novartis, ONO, Roche. All other authors have declared no conflicts of interest.